INNATE PHARMA SA (IDD.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:IDD - FR0010331421 - Common Stock
IDD.DE Key Statistics, Chart & Performance
The current stock price of IDD.DE is 1.582 EUR.
IDD.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 65.13 | 42.70B | ||
| 1AE.DE | ARGENX SE | 65.22 | 42.77B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 20.72B | ||
| ABVX.PA | ABIVAX SA | N/A | 7.71B | ||
| 2X1.DE | ABIVAX SA | N/A | 7.64B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.88B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.87B | ||
| 5CV.DE | CUREVAC NV | 6.71 | 876.36M | ||
| NANO.PA | NANOBIOTIX | N/A | 856.31M | ||
| IVA.PA | INVENTIVA SA | N/A | 782.22M | ||
| 6IV.DE | INVENTIVA SA | N/A | 753.57M | ||
| PHIL.MI | PHILOGEN SPA | 20 | 666.67M |
Related stock screener links
About IDD.DE
Company Profile
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Company Info
INNATE PHARMA SA
117 avenue de Luminy, Bp 30191
Marseille PACA FR
Employees: 181
Phone: 33430303030
INNATE PHARMA SA / IDD.DE FAQ
Can you describe the business of INNATE PHARMA SA?
Innate Pharma SA is a global, clinical-stage biotechnology company, which engages in developing immunotherapies for cancer patients. The company is headquartered in Marseille, Paca and currently employs 181 full-time employees. The company went IPO on 2006-10-31. The firm identifies and characterizes drug candidates, selects indications, and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The firm develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The firm operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk. The company also has a multi-product partnership with AstraZeneca.
Can you provide the latest stock price for INNATE PHARMA SA?
The current stock price of IDD.DE is 1.582 EUR. The price increased by 0.25% in the last trading session.
Does INNATE PHARMA SA pay dividends?
IDD.DE does not pay a dividend.
What is the ChartMill rating of INNATE PHARMA SA stock?
IDD.DE has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is INNATE PHARMA SA (IDD.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IDD.DE.
Is INNATE PHARMA SA (IDD.DE) expected to grow?
The Revenue of INNATE PHARMA SA (IDD.DE) is expected to decline by -26.21% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the ownership structure of INNATE PHARMA SA (IDD.DE)?
You can find the ownership structure of INNATE PHARMA SA (IDD.DE) on the Ownership tab.
IDD.DE Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to IDD.DE.
IDD.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to IDD.DE. IDD.DE may be in some trouble as it scores bad on both profitability and health.
IDD.DE Financial Highlights
Over the last trailing twelve months IDD.DE reported a non-GAAP Earnings per Share(EPS) of -0.55. The EPS decreased by -29.32% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.46% | ||
| ROE | -894.94% | ||
| Debt/Equity | 11.63 |
IDD.DE Forecast & Estimates
9 analysts have analysed IDD.DE and the average price target is 5.58 EUR. This implies a price increase of 252.64% is expected in the next year compared to the current price of 1.582.
For the next year, analysts expect an EPS growth of -32.84% and a revenue growth -26.21% for IDD.DE